---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-21-012629"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2021-11-26T23:59:59+00:00"
generated_at: "2026-06-28T05:15:36.783020+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma fails Nasdaq independent director rule; cure until Nov 2022

## Summary
- Received Nasdaq notice on Nov 23, 2021 for non-compliance with Listing Rule 5605 after appointing Michael Breen as Executive Chairman.
- Breen resigned from Audit, Compensation, and Nominating Committees on Nov 23, 2021, triggering the deficiency.
- Cure period runs until earlier of next annual shareholders' meeting or Nov 8, 2022 (or May 9, 2022 if meeting before).
- Company is reviewing independent director candidates and expects to regain compliance within the cure period.

## SEC filing metadata
- accession: 0001654954-21-012629
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2021-11-26T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000165495421012629/0001654954-21-012629-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000165495421012629/gtbp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-21-012629
- JSON: https://secwatch.observer/filing/0001654954-21-012629.json
- Plain text: https://secwatch.observer/filing/0001654954-21-012629.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.